Ocular Therapeutix (OCUL) Misses Q2 EPS by 4c

Ocular Therapeutix (NASDAQ: OCUL) reported Q2 EPS of ($0.39), $0.04 worse than the analyst estimate of ($0.35). Revenue for the quarter came in at $13.46 million versus the consensus estimate of $13.56 million.

For earnings history and earnings-related data on Ocular Therapeutix (OCUL) click here.

You May Also Be Interested In

• Alphabet added to Dow Jones Industrial Average, Verizon dropped
• After-Hours Stock Movers: FDX, CBRS, NKE
• Ocular Therapeutix (OCUL) PT Raised to $25 at H.C. Wainwright